US · TNGX · BIOTECHNOLOGY
Tango Therapeutics, Inc. (TNGX) intrinsic value and stock valuation
$21.73as of 2026-11-21 · Mkt cap 3.37B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Tango Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values TNGX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TNGX’s statements →
Tango Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37M |
| Operating income | -$-111.29M | -$-145.59M | -$-114.17M | -$-111.07M | -$-58.19M |
| Net income | -$-101.59M | -$-130.3M | -$-101.74M | -$-108.18M | -$-58.23M |
| EPSd | -$-874.49K | -$-1.19M | -$-1.08M | -$-1.23M | -$-937.53K |
| Operating cash flow | -$-138.89M | -$-131.5M | -$-117.98M | -$-109.08M | -$-59.53M |
| Capital expenditure | -$-1.05M | -$-750K | -$-1.53M | -$-7.69M | -$-1.84M |
| Free cash flow | -$-139.93M | -$-132.25M | -$-119.51M | -$-116.77M | -$-61.36M |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Total debt | $33.6M | $36.5M | $38.9M | $41.1M | $1.5M |
| Net debt | -$-78.71M | -$-33.04M | -$-27.46M | -$-18.84M | -$-141.24M |
| Total equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.8M |
| Cash and short-term investments | $343.1M | $257.9M | $336.9M | $366.1M | $485.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37M |
| Cost of revenue | $2.28M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $60.1M | $42.1M | $36.5M | $24.9M | $37M |
| Research and development expenses | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M |
| Selling, general and administrative expenses | $41.5M | $43.8M | $35.5M | $30M | $17.6M |
| Other expenses | -$-2.28M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $171.4M | $187.7M | $150.7M | $135.9M | $95.2M |
| Cost and expenses | $173.7M | $187.7M | $150.7M | $135.9M | $95.2M |
| Interest income | $5.63M | $7.89M | $6.62M | $1.46M | $490K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $2.28M | $2.5M | $2.42M | $1.61M | $900K |
| Ebitda | -$-99.31M | -$-127.59M | -$-99.19M | -$-106.51M | -$-57.05M |
| Operating income | -$-111.29M | -$-145.59M | -$-114.17M | -$-111.07M | -$-58.19M |
| Total other income/expenses, net | $9.7M | $15.5M | $12.6M | $2.95M | $250K |
| Income before tax | -$-101.59M | -$-130.09M | -$-101.61M | -$-108.12M | -$-57.94M |
| Income tax expense | $0.00 | $210K | $130K | $50K | $290K |
| Net income | -$-101.59M | -$-130.3M | -$-101.74M | -$-108.18M | -$-58.23M |
| Weighted average shares outstanding | $116.2M | $109.2M | $94.6M | $87.8M | $62.1M |
| Weighted average diluted shares outstanding | $116.2M | $109.2M | $94.6M | $87.8M | $62.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $343.1M | $257.9M | $336.9M | $366.1M | $485.3M |
| Net receivables | $0.00 | $0.00 | $0.00 | $2M | $2M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $353.8M | $266.3M | $346.5M | $375.3M | $492.3M |
| Property, plant and equipment, net | $42.5M | $47.6M | $53.4M | $57.8M | $6.09M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $44.9M | $50.2M | $56M | $61.2M | $7.82M |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Accounts payable | $1.18M | $1.6M | $2.79M | $4.45M | $3.23M |
| Short-term debt | $2.74M | $2.45M | $2.08M | $1.77M | $1.5M |
| Deferred revenue | $0.00 | $17.6M | $25.7M | $31.8M | $26M |
| Total current liabilities | $21.7M | $38.2M | $45.9M | $55.6M | $40.7M |
| Long-term debt | $30.8M | $34M | $36.8M | $39.4M | $0.00 |
| Deferred revenue, non-current | $0.00 | $44.8M | $66.7M | $92.1M | $114.7M |
| Total non-current liabilities | $30.8M | $78.8M | $103.5M | $131.5M | $114.7M |
| Capital lease obligations | $2.74M | $36.5M | $38.9M | $41.1M | $1.5M |
| Total liabilities | $52.5M | $117M | $149.5M | $187M | $155.4M |
| Common stock | $140K | $110K | $100K | $90K | $90K |
| Retained earnings | -$-603.15M | -$-501.56M | -$-371.26M | -$-269.51M | -$-161.34M |
| Accumulated other comprehensive income (loss) | $220K | $340K | $190K | -$-3.71M | -$-770K |
| Total equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.8M |
| Total investments | $230.9M | $188.4M | $270.5M | $306.2M | $342.5M |
| Total debt | $33.6M | $36.5M | $38.9M | $41.1M | $1.5M |
| Net debt | -$-78.71M | -$-33.04M | -$-27.46M | -$-18.84M | -$-141.24M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-101.59M | -$-130.3M | -$-101.74M | -$-108.18M | -$-58.23M |
| Depreciation and amortization | $2.28M | $2.5M | $2.42M | $1.61M | $900K |
| Stock-based compensation | $26.4M | $28.9M | $19.1M | $14.2M | $7.83M |
| Change in working capital | -$-67.2M | -$-31.75M | -$-37.97M | -$-18.49M | -$-11.35M |
| Accounts receivable | $0.00 | $0.00 | $2M | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-820K | -$-1.18M | -$-1.71M | $1.1M | $1.23M |
| Net cash provided by operating activities | -$-138.89M | -$-131.5M | -$-117.98M | -$-109.08M | -$-59.53M |
| Investments in property, plant and equipment | -$-1.05M | -$-750K | -$-1.53M | -$-7.69M | -$-1.84M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-40.87M | $86.1M | $41.4M | $26.4M | -$-183.43M |
| Common stock issued | $222.5M | $41.7M | $80M | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $222.5M | $47.7M | $82.4M | $1.61M | $357.3M |
| Net change in cash | $42.8M | $2.29M | $5.85M | -$-81.07M | $114.4M |
| Cash at end of period | $114.9M | $72.1M | $69.8M | $64M | $145M |
| Operating cash flow | -$-138.89M | -$-131.5M | -$-117.98M | -$-109.08M | -$-59.53M |
| Capital expenditure | -$-1.05M | -$-750K | -$-1.53M | -$-7.69M | -$-1.84M |
| Free cash flow | -$-139.93M | -$-132.25M | -$-119.51M | -$-116.77M | -$-61.36M |
Line items
Line items
Line items
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
- CEO
- Malte Peters
- Employees
- 137
- Beta
- 1.13
Explore
Frequently asked questions
What is the intrinsic value of Tango Therapeutics, Inc. (TNGX)?
Tango Therapeutics, Inc. (TNGX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TNGX undervalued?
TNGX trades at a price of $21.73 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.